Amarin Corp Plc (AMRN)

[Dancing in the dark]

Amarin does the following:

1. Begins negotiations with the generics for a strategic agreement to become the sole manufacture of the drug for the generics companies Authorized generic. Remember the manufacturing process to make Vascepa is very challenging an expensive. We also have the supply chain in our favor and the pricing is very competitive with our brand.
2. This will allow Hikma and Ready to capitalize on the current and future research of the drug including potential new indications.
3. It will allow the generics to maximize the revenue from all indications without a lot of competition. Amarin's sales force would be out their promoting and building the market place
4. Amarin could still make several hundred million in this type of agreement in the US which is better than what they would make fighting all of the generics.
5.This model has become popular in the pharma industry over the past few years with very similar situations that Amarin is currently in.

Go back review the drug Adderall ER which was a billion dollar brand until it lost its Appeals Case but then negotiated a manufacturing agreement with the generic company because of how difficult and costly it was to manufacture Adderall ER

6. Amarin's situation is errily similar to the situation a few years back with Adderall SR. Shire still generated annually over 6 hundred million a year manufacturing the authorized generic for the generic company for several years after losing the appeals case.

7. Finally, why did the appeals court come back with their decision less than 24 hours after the Oral arguments?

you lost me at step 1. amarin does manufacture, encapsulate or package vascepa. amarin is merely the marketer.